Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

SERB has assumed responsibility for the commercialization of Hansa’s Idefirix across the EU, UK, Switzerland, Norway, Liechtenstein, Iceland, and the MENA region. The transaction significantly strengthens Hansa’s financial position and supports a planned US launch, contingent on US approval. Overall, the deal is a positive step for commercialization momentum with a clear regulatory gating item.

Analysis

SERB has assumed responsibility for the commercialization of Hansa’s Idefirix across the EU, UK, Switzerland, Norway, Liechtenstein, Iceland, and the MENA region. The transaction significantly strengthens Hansa’s financial position and supports a planned US launch, contingent on US approval. Overall, the deal is a positive step for commercialization momentum with a clear regulatory gating item.